Medprin Regenerative Medical Technologies Co. Ltd.

Guangzhou Medprin Regenerative Medical Technologies announced that its research and development project, Absorbable Hemostatic Fluid Gelatin, has officially entered the clinical trial stage. The product is a Class III medical device used to assist hemostasis during surgical procedures. The company stated that this move will help enrich its product line in other surgical fields, but there are uncertainties in clinical trials and regulatory approval for market launch, and it is currently unable to predict the impact on its financial performance.

Medprin Regenerative Medical Technologies released its 2026 interim report on August 21, 2026. The company's total operating revenue was 190 million yuan, and net profit attributable to the parent company was 56.5805 million yuan. Net cash inflow from operating activities was 48.2026 million yuan, a decrease of 8.3184 million yuan compared with the same period last year, down 14.72 percent year on year. The company's latest asset-liability ratio was 9.97 percent, up 0.29 percentage points from the previous quarter. Gross margin was 78.96 percent, down 1.63 percentage points from the same period last year. The latest return on equity was 6.97 percent, and diluted earnings per share was 0.85 yuan. The company had 8,030 shareholders, and the top ten shareholders held 38.4961 million shares, accounting for 57.41 percent of total share capital.

Maipu Medical released its 2026 half-year report. First-half operating revenue was 190 million yuan, up 20.3% year on year. Net profit attributable to the parent was 56.58 million yuan, up 19.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 53.94 million yuan, up 17.3% year on year. Second-quarter operating revenue was 111 million yuan, up 32.5% year on year, and net profit attributable to the parent was 35.87 million yuan, up 55.0% year on year. As of the end of the second quarter, the company's total assets were 901 million yuan, up 0.7% from the end of the previous year, and net assets attributable to the parent were 811 million yuan, up 1.7% from the end of the previous year. The company said its main operating businesses and main products had not undergone major changes, that it continued to make high-intensity research and development investments, focused on the neurosurgery field, and steadily advanced its overseas channel layout.